case_images: PMC7334770_01
case_images: (a) PET/CT scan prior to start of dabrafenib/trametinib combination therapy showing multiple subcutaneous metastases. (b) PET/CT scan 4 months after initiation of BRAFi/MEKi therapy showing resolution of previously noted subcutaneous metastasis.
case_images: CRIONM2020-4392562.001.jpg
case_images: PMC7334770_01_CRIONM2020-4392562.001.jpg
case_images: fig1
case_images: In July of 2018, PET/CT showed near-complete response to treatment, with resolution of the pulmonary and subcutaneous nodules (Figure 1).
case_images: (a) PET/CT scan prior to start of ipilimumab/nivolumab immunotherapy showing FDG avid 2.8 x 3.9 cm left inguinal lymphadenopathy. (b) PET/CT scan 4 months after reinitiation of ipilimumab/nivolumab immunotherapy showing near-complete resolution of the left iliac lymphadenopathy.
case_images: CRIONM2020-4392562.002.jpg
case_images: PMC7334770_01_CRIONM2020-4392562.002.jpg
case_images: fig2
case_images: PET/CT in late-July 2019 showed mixed response to therapy, with a significant decrease in nodal and subcutaneous FDG avidity with a stable small left hepatic lobe lesion that was previously noted in November 2018 (Figure 2).